Daiichi Sankyo is poised to report significantly lower full-year profit for fiscal year 2025, primarily due to a 95 billion ...
President Donald Trump is set to fire FDA Commissioner Marty Makary, The Wall Street Journal reports, citing sources familiar ...
After losing the top spot in March to Johnson & Johnson’s immunology drug Tremfya, AbbVie’s rival med Skyrizi is back as the ...
With an FDA decision date looming for its Duchenne muscular dystrophy (DMD) treatment deramiocel, Capricor Therapeutics has filed a ...
With its largest-ever acquisition, Angelini gains 24-year-old Catalyst, which was listed on the Nasdaq in 2006. Catalyst ...
Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. | Summit's ...
GSK is teaming up with “Modern Family” stars Julie Bowen and Ty Burrell to help get out the messaging: “ask to be sure” about ...
Gilead raised its previous guidance of $800 million in revenues from the long-acting PrEP injectable Yeztugo based on a ...
In the latest update to COVID and vaccine-related discourse bubbling up at the FDA, agency officials have recently blocked ...
After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...
Alnylam with an untitled letter over the consumer website for Amvuttra, accusing the biotech | The FDA has hit Alnylam with ...
Insulet has always been a strong leader in the medtech industry when it comes to its marketing game—and the diabetes device maker isn’t looking to rest on its laurels. | Insulet has always been a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results